Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,628 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
荣昌生物自愿披露关于泰它西普治疗IgA肾病适应症的附条件上市申请获得批准的公告
Regulatory Filings Classification · 75% confidence The document is a voluntary corporate announcement by Rongchang Biotech regarding conditional market approval granted by the National Medical Products Administration for a drug (泰它西普注射液) treating IgA nephropathy. It contains product and clinical trial details, risk warnings, and compliance statements, but no financial statements, share transactions, management changes, earnings data, or other specialized filing content. It does not fit into any specific category like earnings release, capital update, or AGM materials. Therefore, it falls into the general regulatory announcements category (Regulatory Filings).
2026-06-08 Chinese
荣昌生物2025年年度股东会会议资料
Proxy Solicitation & Information Statement Classification · 80% confidence The document is the full “股东会会议资料” (shareholders’ meeting materials) for the company’s 2025 Annual General Meeting, containing the meeting notice, agenda, detailed proposals (board report, financial statements, annual report, auditor re-appointment, capital changes, remuneration plans, etc.) and supporting information. It is clearly the proxy/AGM information circular sent to shareholders to provide background on each resolution and solicit their votes, not just an announcement or a live transcript. This fits the definition of Proxy Solicitation & Information Statement (PSI).
2026-06-08 Chinese
荣昌生物自愿披露关于泰它西普治疗干燥综合征（干燥病）适应症的上市申请获得批准的公告
Regulatory Filings Classification · 82% confidence The document is a voluntary corporate announcement disclosing that the company’s new drug indication has been approved by the national regulator. It contains no financial statements, no board or management changes, no capital or dividend information. It is a general regulatory announcement about product approval and falls under miscellaneous Regulatory Filings.
2026-06-08 Chinese
H股公告
Regulatory Filings Classification · 78% confidence The document is a Hong Kong listing rule announcement (“須予披露交易”) by RemeGen Co., Ltd. detailing its board approval and multiple agreements to use idle funds to purchase structured wealth management products from a bank. It is neither a financial statement (10-K/IR), management discussion (MDA), nor an operational transcript, dividend notice, share issue, nor proxy material. It is a routine regulatory announcement of a material transaction under the Listing Rules, therefore best classified under general regulatory filings.
2026-06-01 Chinese
H股公告
Regulatory Filings Classification · 85% confidence The document is an announcement under the Hong Kong Listing Rules (Chapter 14) notifying shareholders of a “disclosable transaction” – the company’s purchase of wealth management products with idle funds. It contains no financial statements or earnings data, nor is it a board change, report publication, dividend notice, or share issue. It is a regulatory announcement mandated by the exchange, so it falls into the general Regulatory Filings category (RNS).
2026-05-26 Chinese
H股公告
Regulatory Filings Classification · 90% confidence The document is a Hong Kong stock exchange announcement under the Listing Rules describing a discloseable transaction (purchase of wealth‐management products using idle funds) and the requisite board approvals and regulatory disclosures. It is a compliance announcement rather than a financial report, investor presentation, dividend notice, or share transaction. No actual financial statements are included. Therefore it falls under general regulatory filings (RNS).
2026-05-20 Chinese

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.